Bristol-Myers Squibb Partners With CytomX, Incyte in Immunotherapy

Bristol-Myers Squibb Co. and CytomX Therapeutics Inc. have agreed to collaborate to develop and commercialize various immuno-oncology therapies using CytomX's Probody Platform, the companies said Tuesday.



from WSJ.com: US Business http://ift.tt/1kbs0qN

via IFTTT